Home › Funds › Wildcat Capital Management, LLC › ALLO
Wildcat Capital Management, LLC position in ALLO
ALLOGENE THERAPEUTICS INC · Health Care
Wildcat Capital Management, LLC reported holding 2,920,787 shares of ALLO (ALLOGENE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.7M, representing 2.68% of its reported portfolio and ranking #2 among its reported holdings. Wildcat Capital Management, LLC has disclosed ALLO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Wildcat Capital Management, LLC's ALLO position evolved
Wildcat Capital Management, LLC first disclosed a stake in ALLO in Q3 2023 at 1,920,787 shares (US$6.1M). The position peaked in Q3 2024 at 2,920,787 shares, worth US$8.2M. Across 13 filings, Wildcat Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 2,920,787 shares valued at US$4.7M. Notable position changes include a 52% increase in Q2 2024 (shares rose 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.92M | $6.09M | New |
| Q4 2023 | 1.92M | $6.17M | Hold |
| Q1 2024 | 1.92M | $7.88M | Hold |
| Q2 2024 | 2.92M | $6.81M | Add |
| Q3 2024 | 2.92M | $8.18M | Hold |
| Q4 2024 | 2.92M | $6.22M | Hold |
| Q1 2025 | 2.92M | $4.26M | Hold |
| Q2 2025 | 2.92M | $3.12M | Hold |
| Q3 2025 | 2.92M | $3.62M | Hold |
| Q4 2025 | 2.92M | $4.00M | Hold |
| Q1 2026 | 2.92M | $7.13M | Hold |
| Q2 2026 | 2.92M | $6.08M | Hold |
| Q3 2026 | 2.92M | $4.67M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALLO and 13F data
ALLO (ALLOGENE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in ALLO — the largest reported positions include Frazier Life Sciences Management, L.P. (US$46.7M), TPG GP A, LLC (US$38.9M), PFIZER INC (US$36.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALLO
- Frazier Life Sciences Management, L.P. 22.45M sh · $46.69M · Q2 2026
- TPG GP A, LLC 18.72M sh · $38.93M · Q2 2026
- PFIZER INC 22.03M sh · $36.35M · Q3 2026
- Sio Capital Management, LLC 13.32M sh · $27.71M · Q2 2026
- GordonMD Global Investments LP 5.30M sh · $11.02M · Q2 2026
- Patient Square Capital LP 4.55M sh · $7.28M · Q3 2026
- DAFNA Capital Management LLC 2.00M sh · $4.16M · Q2 2026
More on Wildcat Capital Management, LLC
FAQ
How long has Wildcat Capital Management, LLC held ALLO?
Wildcat Capital Management, LLC has disclosed ALLO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Wildcat Capital Management, LLC's current position in ALLO?
As of Q3 2026, Wildcat Capital Management, LLC holds 2.92M shares of ALLO (ALLOGENE THERAPEUTICS INC), valued at $4.67M, representing 2.68% of its reported portfolio and ranking #2.
Has Wildcat Capital Management, LLC been buying or selling ALLO?
In the latest 13F filing (Q3 2026), Wildcat Capital Management, LLC held unchanged its position in ALLO. The position peaked in Q3 2024 at 2.92M shares.
Which other funds hold ALLO?
Other major institutional holders of ALLO include Frazier Life Sciences Management, L.P., TPG GP A, LLC, PFIZER INC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.